Evaluation on stability process of Brucella melitensis - Rev. 1 vaccine in Iran

Authors

  • A. Pourahmadi
  • A.M. Behroozikhah
  • M. Moghadampour
  • S. Alamian
Abstract:

According to the reports of WHO, stability of Rev.1 vaccine should take more than one year, while the expiring date for the vaccine produced in Iran is 3 to 4 months, therefore any attempt to elongate the stability of this vaccine can solve many problems of the production including the request of Veterinary Organization of Iran in this regard. The objective of this study was to increase the stability of this vaccine using various preserving materials in lyophilisation process. Nine effective preserving materials in two different volumes and different lyophilisation procedures were examined .We found that the best preserving materials which are added to the base formula for Rev.1 vaccine is consisted of bactocasitone %2.5, sucrose %5, L-glutamic acid sodium salt %1. As a result we formulate the most suitable compound in terms of bacterial mass after lyophilisation. The other factor which had to be improved was the duration of liquid form of the vaccine before lyophilisation process which causes reduction of the organism %50 to %70 per dose of the vaccine. This problem was solved by reduction of liquid phase. The most important practical result of this research was finding the optimum condition for the dose of the Rev.1 vaccine as 1-4×109 CFU and 0.5- 3× 106 CFU for the Reduced dose with 1-2% humidity and the vacuum of 1-2×10-3. In these conditions the vaccine can be kept and used for more than 8 months. Hence the expiring date of the present vaccines under these conditions would be increased up to eight months.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

evaluation on stability process of brucella melitensis - rev. 1 vaccine in iran

according to the reports of who, stability of rev.1 vaccine should take more than one year, while the expiring date for the vaccine produced in iran is 3 to 4 months, therefore any attempt to elongate the stability of this vaccine can solve many problems of the production including the request of veterinary organization of iran in this regard. the objective of this study was to increase the sta...

full text

First Report of Isolation of Brucella melitensis, Vaccine Strain Rev.1 as a Source of Cattle Infection in Iran

Brucellosis is a worldwide zoonosis causing reproductive failures in livestock. It is shown that although the vaccine can prevent abortion, it does not provide complete protection against infection. So that vaccination of ewes with Rev.1 biotype can be a source of cattle and even human Brucellosis. The aim of this study was to evaluate possibility of Brucella cross-infection in cattle from Bruc...

full text

Deletion of the GI-2 integrase and the wbkA flanking transposase improves the stability of Brucella melitensis Rev 1 vaccine

Brucella melitensis Rev 1 is the best vaccine available for the prophylaxis of small ruminant brucellosis and, indirectly, for reducing human brucellosis. However, Rev 1 shows anomalously high rates of spontaneous dissociation from smooth (S) to rough (R) bacteria, the latter being inefficacious as vaccines. This S-R instability results from the loss of the O-polysaccharide. To overcome this pr...

full text

Innocuity and immune response to Brucella melitensis Rev.1 vaccine in camels (Camelus dromedarius).

A field trial was conducted in a camel brucellosis-free herd to evaluate antibody response to the Brucella melitensis Rev.1 vaccine in camels and assess shedding of the vaccine strain in milk. Twenty eight camels were divided into four groups according to their age and vaccination route. Groups A (n=3) and B (n=3) consisted of non-pregnant lactating female camels, vaccinated through subcutaneou...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 64  issue 2

pages  85- 90

publication date 2009-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023